Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. PRIM
6. META
7. DPZ
8. N2EW34
9. INTC
10. IMNN

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (T

October 22, 2021 6:45 AM EDT

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS 10) and Who Have Not Received Prior Chemotherapy for Metastatic Disease

KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From the Phase 3 KEYNOTE-355 Study

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European... More